



Biotech Daily

Thursday January 27, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ATOMO UP 12.5%; IMMUTEP DOWN 7%**
- * **SOMNOMED H1 RECEIPTS UP 19% TO \$35m**
- * **CRONOS H1 RECEIPTS: \$29m**
- * **ALCIDION H1 RECEIPTS UP 52% TO \$16.4m**
- * **MEDLAB H1 RECEIPTS UP 87% TO \$4.8m**
- * **ANTERIS RECEIPTS UP 14% TO \$8.3m**
- * **MICRO-X H1 RECEIPTS DOWN 66% TO \$1.2m**
- * **IMRICOR RECEIPTS UP 27% TO \$1.5m**
- * **VIVAZOME, ANU WORK ON EXOSOMES FOR RETINAL DISEASE**
- * **\$283k HANGZHOU ZEDE DEAL TAKES RESONANCE TO CHINA**
- * **NZ APPROVES ATOMO'S ACCESS BIO COVID-19 RAPID ANTIGEN TEST**
- * **TELIX DOSES 1st TLX591 PROSTATE CANCER TREATMENT PATIENT**
- * **US PATENT FOR CHIMERIC CHLOROTOXIN ANTIGEN RECEPTORS**
- * **JAPAN PATENT FOR CYNATA CYMERUS STEM CELLS**
- * **RESAPP: PROF ANTONIO ANZUETO, PROF JOAN SORIANO ADVISERS**

MARKET REPORT

The Australian stock market fell 1.77 percent on Thursday January 27, 2022, with the ASX200 down 123.3 points to 6,838.3 points. Twelve of the Biotech Daily Top 40 companies were up, 20 fell and eight traded unchanged. All three Big Caps fell.

Atomo was the best, up 2.5 cents or 12.5 percent to 22.5 cents, with 7.55 million shares traded. Compumedics and Next Science climbed five percent or more; Alcidion improved 4.4 percent; Genetic Signatures, Impedimed, Kazia and Resonance were up more than three percent; with Cynata, Emvision, Micro-X and Uscom up by more than two percent.

Immutep led the falls, down 2.5 cents or 6.6 percent to 35.5 cents, with 5.85 million shares traded. Amplia and Clinuvel fell more than six percent; Nanosonics, Neuren, Oncosil and Pro Medicus lost five percent or more; Avita, Cochlear and Polynovo retreated more than four percent; CSL, Starpharma and Resmed were down more than three percent; Dimerix, Opthea, Paradigm, Proteomics, Telix and Universal Biosensors shed more than two percent; with Medical Developments, Mesoblast, Pharmaxis and Volpara down by one percent or more.

SOMNOMED

Somnomed says receipts from customers for the six months to December 31, 2021 was up 19.1 percent to \$34,880,000 compared to the prior corresponding period.

Somnomed said its receipts from customers for its sleep apnoea treatments for the three months to December 31, 2021 was up 15.2 percent to \$18,700,000.

The company said that it was \$2,233,000 cashflow positive for the quarter, with cash and equivalents of \$17,571,000 compared to \$25,229,000 at December 31, 2020.

Somnomed was up four cents or two percent to \$2.05.

CRONOS AUSTRALIA

Cronos says receipts from customers for the six months to December 31, 2021 was \$28,554,950.

Last year, Cronos said it had acquired the Varsity Lakes, Gold Coast, Queensland-based CDA Health (formerly Cannabis Doctors Australia) which generated more than \$21 million in sales in 2020-'21 (BD: Sep 14, Dec 16, 2021).

The company said its receipts from customers from medical marijuana sales for the three months to December 31, 2021 was \$16,473,836, it was \$6,745,541 cash flow positive for the three months to December 31, 2021, with cash and cash equivalents of \$12,943,869.

Cronos was unchanged at 27 cents.

ALCIDION

Alcidion says receipts from customers for the six months to December 31, 2021 was up 51.9 percent to \$16,406,000, compared to the prior corresponding period.

Alcidion said its receipts from customers for its patient management software for the three months to December 31, 2021 was up 125.2 percent to \$9,852,000.

The company said it was \$1,544,000 cashflow positive with cash and cash equivalents of \$18,938,000 compared to \$12,541,356 at December 31, 2020.

Alcidion was up one cent or 4.4 percent to 23.5 cents with four million shares traded.

MEDLAB CLINICAL

Medlab says receipts from customers for the six months to December 31, 2021 was up 86.9 percent to \$4,799,000 compared to the prior corresponding period.

Medlab said its receipts from customers for its food additives for the three months to December 31, 2021 were up 122.0 percent to \$2,786,000.

The company said that it was \$645,000 cashflow positive for the three months to December 31, 2021, with cash and cash equivalents of \$11,220,000.

Medlab was unchanged at 12.5 cents.

ANTERIS TECHNOLOGIES

Anteris says receipts from customers for the 12 months to December 31, 2021 were up 14.0 percent to \$8,299,000 compared to the prior corresponding period.

Anteris said its receipts for manufacturing heart valves for the Burlington, Massachusetts-based Le Maitre Vascular for the three months to December 31, 2021 were up 130.9 percent to \$3,029,000, it had a cash burn of \$5,393,000 for the three months to December 31, 2021, with cash and equivalents of \$21,300,000 at December 31, 2021.

Anteris fell \$1.11 or 6.8 percent to \$15.19.

[MICRO-X](#)

Micro-X says receipts from customers for the six months to December 31, 2021 fell 66.3 percent to \$1,182,000, compared to the prior corresponding period.

Micro-X said its receipts from customers from the sale of its mobile X-Ray units for the three months to December 31, 2021 fell 72.0 percent to \$455,000.

The company said that it had a cash burn of \$5,263,000 for the three months to December 31, 2021, with cash and cash equivalents of \$19,944,000 compared to \$12,846,000 at December 31, 2020.

Micro-X was up half a cent or 2.3 percent to 22.5 cents.

[IMRICOR MEDICAL SYSTEMS](#)

Imricor says receipts from customers for the 12 months to December 31, 2021 was up 27.4 percent to \$US1,079,000 (\$A1,524,000) compared to last year.

Imricor said its receipts from customers from its cardiac ablation system for the three months to December 31, 2021 fell 4.7 percent to \$US341,000.

The company said that it had a cash burn of \$US3,972,000 for the three months to December 31, 2021, with cash and cash equivalents of \$US18,516,000 compared to \$US25,140,000 at December 31, 2020.

Imricor fell one cent or one percent to 99 cents.

[VIVAZOME THERAPEUTICS PTY LTD](#)

Vivazome says it will collaborate with the Australian National University on exosome therapies for age-related macular degeneration.

Vivazome said that the research project, titled 'The use of extracellular vesicles (EVs) for therapeutic RNA delivery as a novel treatment for retinal degenerations', was supported by a \$165,400 grant from the University's Research Support Program 2022.

The company said it would work with the ANU School of Medicine and Psychology, Canberra Health Services, Sydney University, the Save Sight Institute, Melbourne's La Trobe University and Adelaide's Flinders University.

Vivazome said that the team had expertise in retinal extracellular vesicles, production and definition of scalable clinical grade extracellular vesicles, extracellular vesicles as therapeutics for neurodegeneration, retinal disease models and clinical ophthalmology.

The company said that the project would investigate human extracellular vesicles as a delivery system for therapeutic micro-RNA (miRNA) cargo.

Vivazome said it would identify candidate extracellular vesicles delivery vehicles; test candidate extracellular vesicles delivery vehicles in a model of retinal degeneration; and load key miRNA cargo into extracellular vesicles for delivery to the degenerating retina.

Vivazome chief executive officer Dr David Haylock said that Prof Riccardo Natoli and his team were "recognized as leading the field in understanding the roles that RNA and extracellular vesicles play in retinal degeneration".

"Vivazome will supply its proprietary extracellular vesicles and provide its expertise in extracellular vesicle biology and analytics," Dr Haylock said.

Prof Natoli said that "age-related macular degeneration is the leading cause of blindness in the Western World, with no effective treatments".

"Our preliminary findings show that supplementation of healthy retinal [extracellular vesicles] with specific miRNA species protected the retina against degeneration," Prof Natoli said.

Vivazome is a private company.

RESONANCE HEALTH

Resonance says China's Hangzhou Zede Pharma-Tech will pay about \$US200,000 (A\$283,000) to use its Ferriscan to measure liver-iron in a phase IIb trial.

Resonance said that the 14-month agreement would allow Zede Pharma-Tech to use the magnetic resonance imaging-based Ferriscan and its Perth service centre to measure and quantify the liver-iron-concentration at up to five time-points in trial participants to assess the safety and efficacy of a new treatment for severe iron overload in transfusion-dependent thalassemia patients.

The company said the agreement was its first entry into China market, and that the agreement could be extended beyond 14 months.

Resonance said it was "the first time Resonance Health has been contracted by a Chinese pharmaceutical company".

The company said there was "a high prevalence of thalassemia in several Chinese provinces, particularly in ... Guangxi, Yunnan, Guangdong, Fujian and Sichuan".

Resonance managing-director Mitchell Wells said the entry into China was "a significant milestone in our strategy to access new much larger markets with our products".

"The quantum of people that could benefit from our devices in China is boggling and we stand ready to support Zede Pharma in its development of a new chelation drug therapy for thalassemia patients globally," Mr Wells said.

"To launch in China in this manner, with the provision of services to a Chinese pharma is tremendous news and the best possible way to enter this market," Mr Welss said.

"China is an enormous potential market for our products and services, with very high prevalence of thalassemia compared to other nations," Mr Wells said.

"I hope that our work with Zede Pharma is the beginning of a long and strong relationship with them and we look forward to helping them address the enormous challenge that thalassemia poses to patients in China and globally," Mr Wells said.

Resonance was up half a cent or 3.1 percent to 16.5 cents.

ATOMO DIAGNOSTICS

Atomo says the New Zealand Ministry of Health has authorized its Access Bio Atomo-branded rapid antigen tests for professional and self-test use.

Last year, Atomo said that it would sell the Somerset, New Jersey-based Access Bio's severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) test in Australia, New Zealand and India under Atomo-branding (BD: Sep 29, 2021).

Atomo was up 2.5 cents or 12.5 percent to 22.5 cents with 7.55 million shares traded.

TELIX PHARMACEUTICALS

Telix says it has dosed the first of up to 50 patients in its phase I trial of TLX591 lutetium-177-labelled antibodies for the treatment of prostate cancer.

Last year, Telix said it would conduct a phase I study as part of its TLX591 'Prostact' therapeutic program, in parallel with its phase III study (BD: Aug 19, 2021).

Today, Telix said the phase I Prostact Select trial at Brisbane's Princess Alexandra Hospital would explore the bio-distribution and tumor uptake of small molecule and antibody-based targeting in men with metastatic castrate-resistant prostate cancer, to inform optimal patient selection for TLX591 antibody therapy.

Telix chief medical officer Dr Colin Hayward said that dosing the first patient was "a significant milestone for Telix".

Telix fell 19 cents or 2.9 percent to \$6.43 with 1.9 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says the US Patent and Trademark Office has granted a patent for its chlorotoxin (CLTX) chimeric antigen receptor T-cell (Car-T) technology.

Chimeric said the patent was titled 'Chimeric antigen receptors containing a chlorotoxin domain' and covered both CHM1101 and CHM1301.

The US Patent and Trademark Office website said that the patent was filed on October 13, 2016 which implied it would provide patent protection until 2036.

Last year, the company said that its CLTX-Car-T technology received patent protection in Europe (BD: Sep 23, 2021).

Chimeric was unchanged at 22 cents with 1.7 million shares traded.

CYNATA THERAPEUTICS

Cynata says the Japan Patent Office "intends to issue a patent" for its Cymerus mesenchymal stem cell technology.

Cynata said the patent, titled 'Pluripotent Stem Cell Assay,' would protect its intellectual property until November 15, 2037.

Cynata was up one cent or 2.1 percent to 48.5 cents.

RESAPP HEALTH

Resapp says it has appointed Prof Antonio Anzueto and Prof Joan Soriano to its scientific advisory board.

Resapp said that Prof Anzueto was a pulmonary and critical care physician at the University of Texas Health in San Antonio.

The company said that Prof Soriano was a respiratory medical epidemiologist at Spain's Hospital Universitario de la Princesa and Universidad Autónoma de Madrid.

Resapp fell 0.6 cents or 10.3 percent to 5.2 cents with 4.2 million shares traded.